SRC and ovarian cancer: Our data demonstrates different mechanisms by which MAPK signalling can become activated and result in resistance to SRC inhibition in ovarian cancer cells, highlighting the potential for combining SRC inhibitors with small molecule inhibitors of the MAPK pathway.